Detalles de la búsqueda
1.
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21266704
2.
Poor sensitivity of iPSC-derived neural progenitors and glutamatergic neurons to SARS-CoV-2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-501370
3.
A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21262027
4.
Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-193672
5.
Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22277885
6.
SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20140178
7.
Robust and Functional Immunity up to 9 months after SARS-CoV-2 infection: a Southeast Asian longitudinal cohort
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-455901
8.
B.1.1.7 and B.1.351 SARS-CoV-2 variants display enhanced Spike-mediated fusion
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-448011
9.
Syncytia formation by SARS-CoV-2 infected cells
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-202028
10.
The spike-stabilizing D614G mutation interacts with S1/S2 cleavage site mutations to promote the infectious potential of SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-492832
11.
Distinct systemic and mucosal immune responses to SARS-CoV-2
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21251633
12.
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22278699
13.
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20230508
14.
Sex differences in the decline of neutralizing antibodies to SARS-CoV-2
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20230466
15.
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20101832
16.
Cluster of COVID-19 in northern France: A retrospective closed cohort study
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20071134
17.
Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22272066
18.
Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261766
19.
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261769
20.
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-B.1.1.7 or B.1.1.7 SARS-CoV-2 variants.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257393